Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Fish and Richardson
Julphar
Cerilliant
Johnson and Johnson
Covington
UBS
Farmers Insurance
AstraZeneca

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRABECTEDIN

« Back to Dashboard

Clinical Trials for Trabectedin

Trial ID Title Status Sponsor Phase Summary
NCT00002904 Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of ecteinascidin 743 in treating adults with advanced solid tumors.
NCT00003939 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have advanced soft tissue sarcoma.
NCT00005625 Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have previously treated metastatic osteosarcoma.
NCT00005625 Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma Completed Memorial Sloan Kettering Cancer Center Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have previously treated metastatic osteosarcoma.
NCT00017030 Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have unresectable advanced or metastatic soft tissue sarcoma.
NCT00017030 Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma Completed Memorial Sloan Kettering Cancer Center Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have unresectable advanced or metastatic soft tissue sarcoma.
NCT00027508 Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma Terminated National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have malignant mesothelioma that cannot be removed by surgery.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Trabectedin

Condition Name

Condition Name for Trabectedin
Intervention Trials
Sarcoma 11
Soft Tissue Sarcoma 9
Ovarian Cancer 6
Leiomyosarcoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Trabectedin
Intervention Trials
Sarcoma 30
Ovarian Neoplasms 12
Liposarcoma 10
Leiomyosarcoma 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Trabectedin

Trials by Country

Trials by Country for Trabectedin
Location Trials
United States 247
Italy 99
Spain 25
Germany 18
France 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Trabectedin
Location Trials
New York 14
Massachusetts 13
California 12
Pennsylvania 12
Washington 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Trabectedin

Clinical Trial Phase

Clinical Trial Phase for Trabectedin
Clinical Trial Phase Trials
Phase 3 11
Phase 2/Phase 3 1
Phase 2 37
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Trabectedin
Clinical Trial Phase Trials
Completed 28
Recruiting 24
Active, not recruiting 9
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Trabectedin

Sponsor Name

Sponsor Name for Trabectedin
Sponsor Trials
PharmaMar 30
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 12
National Cancer Institute (NCI) 9
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Trabectedin
Sponsor Trials
Other 67
Industry 64
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
AstraZeneca
Medtronic
Covington
McKinsey
Moodys
Harvard Business School
Chubb
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.